We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+13.81%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$2.23B
AUM Growth
-$82.9M
Cap. Flow
-$145M
Cap. Flow %
-6.5%
Top 10 Hldgs %
65.91%
Holding
64
New
5
Increased
3
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
WHWK
Whitehawk Therapeutics
WHWK
+$43.5M
2
SERA icon
Sera Prognostics
SERA
+$19.3M
3
VRDN icon
Viridian Therapeutics
VRDN
+$19.1M
4
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$14M
5
HRMY icon
Harmony Biosciences
HRMY
+$11.3M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$105M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$25.8M
3
CLDX icon
Celldex Therapeutics
CLDX
+$22.7M
4
LEGN icon
Legend Biotech
LEGN
+$19.5M
5
NVAX icon
Novavax
NVAX
+$18.7M

Sector Composition

Rank Sector Weight
1 Healthcare 85.61%
2 Financials 7.21%
3 Materials 7.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
26
Aclaris Therapeutics
ACRS
$813M
$16.9M 0.76%
940,754
-433,525
-32% -$6.95M
MREO
27
Mereo BioPharma
MREO
$52.1M
$16.7M 0.75%
6,907,189
+2,686,251
+64% +$7.11M
VRNA
28
DELISTED
Verona Pharma
VRNA
$15.1M 0.68%
2,749,918
-298,589
-10% -$1.74M
NKTX icon
29
Nkarta
NKTX
$158M
$14.2M 0.64%
512,225
– –
DICE
30
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$13.4M 0.6%
+410,000
New +$14M
GRCL
31
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$13.3M 0.6%
961,359
-366,898
-28% -$4.33M
CRIS icon
32
Curis
CRIS
$9.28M
$12.2M 0.55%
3,884
– –
COGT icon
33
Cogent Biosciences
COGT
$7.29B
$11.9M 0.54%
+1,420,941
New +$10.9M
KDNY
34
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$11.1M 0.5%
872,151
– –
AUPH icon
35
Aurinia Pharmaceuticals
AUPH
$1.91B
$11.1M 0.5%
500,732
– –
CRNX icon
36
Crinetics Pharmaceuticals
CRNX
$8.91B
$10.9M 0.49%
517,280
-1,235,066
-70% -$25.8M
ARQT icon
37
Arcutis Biotherapeutics
ARQT
$3.26B
$10.4M 0.47%
433,585
– –
KURA icon
38
Kura Oncology
KURA
$840M
$9.84M 0.44%
525,262
– –
MRUS
39
DELISTED
Merus
MRUS
$9.72M 0.44%
442,000
– –
DYN icon
40
Dyne Therapeutics
DYN
$4.81B
$9.38M 0.42%
577,642
– –
CDXS icon
41
Codexis
CDXS
$159M
$9.03M 0.41%
388,144
– –
ARWR icon
42
Arrowhead Research
ARWR
$12.4B
$8.58M 0.39%
137,411
– –
EPIX
43
DELISTED
ESSA Pharma
EPIX
$8.45M 0.38%
1,056,067
-495,613
-32% -$7.88M
ZYME icon
44
Zymeworks
ZYME
$1.65B
$8.31M 0.37%
286,064
– –
DSGN icon
45
Design Therapeutics
DSGN
$810M
$7.8M 0.35%
530,991
– –
QTTB icon
46
Q32 Bio
QTTB
$462M
$6.71M 0.3%
47,397
– –
VALN
47
Valneva
VALN
$527M
$6.28M 0.28%
200,000
-200,000
-50% -$6.35M
SNDX icon
48
Syndax Pharmaceuticals
SNDX
$1.73B
$6.12M 0.27%
320,000
– –
STSA
49
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$5.74M 0.26%
1,232,394
– –
PASG icon
50
Passage Bio
PASG
$14.4M
$5.37M 0.24%
26,963
-5,337
-17% -$1.27M
1
2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
LWIC
Leith Wheeler Investment Counsel Vancouver, British Columbia, Canada $1.21B AUM 12.04% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return

Vivo Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Vivo Capital held 64 positions worth $2.23B, down 3.6% from $2.31B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Vivo Capital withdrew a net $145M in Q3 2021, closing 4 positions and reducing 16 holdings. Its most notable exit was Novavax, an estimated $18.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Financials and Materials.

Against the trend, Vivo Capital opened a new position in Whitehawk Therapeutics worth $41.9M.

  • Vivo Capital's largest Q3 2021 buy was Whitehawk Therapeutics: 1,427,213 shares worth $41.9M.
  • Vivo Capital added most to Harmony Biosciences in Q3 2021, an estimated $11.3M increase.
  • Vivo Capital's biggest Q3 2021 reduction was Ascendis Pharma A/S, cutting an estimated $105M.
  • Vivo Capital fully exited Novavax in Q3 2021, selling an estimated $18.7M.
  • Vivo Capital's ten largest holdings make up 66% of its $2.23B portfolio in Q3 2021.
  • Vivo Capital opened 5 new positions and closed 4 in Q3 2021.
  • Vivo Capital's portfolio value fell 3.6% quarter-over-quarter to $2.23B.

Based on Vivo Capital's 13F filing for Q3 2021, filed 15 Nov 2021.